Key facts
- Notable investors include Highlight Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Dejin Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Dejin Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dejin Bio
Manufacturer of recombinant botulinum toxin products intended to support safe and reliable injectable biopharmaceutical use. The company offers recombinant protein expression systems, engineered bacterial strains, and GMP-aligned production capabilities, enabling medical aesthetics providers and neurological disease treatment settings to access consistent product quality with improved safety and controlled manufacturing efficiency.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Dejin Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dejin Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dejin Bio in its N-PORT filings yet. We sweep new filings monthly.